DEEP REGIONAL HYPERTHERMIA
HEATING TUMOURS INSIDE THE PELVIS AND ABDOMEN
Phased-array radiofrequency antennae focus heat at depth โ reaching tumours other hyperthermia systems cannot, and turning treatment-resistant pelvic and abdominal cancers vulnerable to radiation and chemotherapy.
analyticsAt a Glance
- check_circleReaches deep-seated tumours up to 20 cm below the skin surface
- check_circleReal-time temperature mapping using interstitial and luminal probes
- check_circleStandard-of-care addition for cervical cancer in EU guidelines
- check_circlePhase III evidence in cervical cancer, sarcoma, and recurrent rectal disease
What Is Deep Regional Hyperthermia?
Deep regional hyperthermia is a non-invasive cancer treatment that heats a defined body region โ typically the pelvis or abdomen โ to 40โ43ยฐC using external phased-array antennae. Unlike local hyperthermia, which only reaches superficial tumours, regional systems penetrate deeply to treat tumours that other thermal modalities cannot reach.
โDeep regional hyperthermia is the only non-invasive way to heat tumours buried 10โ20 cm inside the body to therapeutic temperatures.โ
How It Differs from Local Hyperthermia
Local hyperthermia uses microwave or radiofrequency antennae placed near the skin and reaches only 3โ4 cm in depth โ suitable for chest wall, head and neck, or melanoma but useless for cervix or bladder. Deep regional systems use a ring of antennae around the body to focus energy at much greater depth.
How It Differs from Whole-Body Hyperthermia
Whole-body hyperthermia raises core temperature systemically using infrared cabinets โ affecting the entire body. Deep regional hyperthermia concentrates heat only in the target anatomy, leaving the rest of the body at normal temperature and avoiding the systemic strain of whole-body treatment.
How Phased-Array Systems Heat Tumours at Depth
Deep regional hyperthermia is a physics problem as much as a medical one โ getting heat past the skin and subcutaneous fat into a tumour buried 15 cm deep without burning the surface. Phased-array radiofrequency systems solve this through a process of focused interference.
Multiple Antennae Surround the Body
The patient lies inside an applicator ring โ typically 4 to 12 radiofrequency antennae arranged in a circle around the pelvis or abdomen. Modern systems like the BSD-2000 Sigma-Eye use 24 antennae in a 3D configuration for finer control.
Phase and Amplitude Are Adjusted to Steer Heat
Each antenna emits radiofrequency waves at slightly different timings (phases) and power levels. The waves constructively interfere at the target tumour location โ concentrating energy there while cancelling out elsewhere. This is the same principle that drives MRI gradient coils and phased-array radar.
Tumour Temperature Reaches 40โ43ยฐC
The interference focus is positioned at the tumour, raising local tissue temperature to the therapeutic range. Surrounding healthy tissue stays near normal because the energy peaks happen only at the target.
Real-Time Temperature Monitoring Guides Adjustments
Temperature probes are placed in body cavities (rectum, bladder, vagina, oesophagus) and sometimes directly inside the tumour via thin catheters. MRI thermometry is also used in advanced systems. The physicist adjusts phases and power continuously to keep the tumour at target temperature without overheating normal tissue.
Leading Clinical Systems
The BSD-2000 (Pyrexar) is the most widely deployed and the system used in landmark phase III trials. The Celsius TCS (Celsius42) is common in European and Chinese centres. The EHY-2000 (Oncotherm) uses capacitive coupling and is widely available in Germany and Asia.
Tumours Treated with Deep Regional Hyperthermia
Deep regional hyperthermia is used for solid tumours of the pelvis and abdomen, almost always combined with radiation, chemotherapy, or both.
| Tumour Site | Common Indication | Combined With | Evidence Strength |
|---|---|---|---|
| Cervical Cancer | Locally advanced (stage IIBโIVA), recurrent pelvic disease | Radiation + cisplatin | Strong โ phase III RCT; guideline-supported in NL |
| Soft Tissue Sarcoma | Retroperitoneal, pelvic, deep extremity | Neoadjuvant ifosfamide-based chemo | Strong โ phase III RCT (EORTC/ESHO 62961) |
| Rectal Cancer | Locally advanced; recurrent after prior CRT | Re-irradiation + capecitabine/5-FU | Moderate โ phase II and retrospective series |
| Bladder Cancer | Muscle-invasive; bladder-preservation protocols | Chemoradiation (cisplatin + RT) | Moderate โ phase II evidence |
| Prostate Cancer | High-risk localised; salvage after radiation | Brachytherapy or external beam radiation | Emerging โ small phase II studies |
| Pancreatic Cancer | Locally advanced unresectable | Gemcitabine or FOLFIRINOX | Investigational โ phase II ongoing |
| Anal Canal Cancer | Locally advanced; recurrent post-CRT | Mitomycin + 5-FU + radiation | Moderate โ single-institution data |
| Peritoneal Metastases | Selected cases for palliation and symptom control | Systemic chemotherapy | Investigational โ small series |
What Happens During a Deep Regional Hyperthermia Session
A typical session takes 90โ120 minutes from arrival to discharge. Patients lie inside the applicator ring while the heating is delivered.
- 1
Pre-Session Setup and Probe Placement
Temperature probes are positioned in nearby body cavities โ typically the rectum, vagina, or bladder โ to monitor heat distribution. For sarcomas or deep tumours, a thin catheter may be placed directly into or adjacent to the tumour under imaging guidance.
- 2
Positioning Inside the Applicator
The patient lies on a treatment table that slides into the centre of the antenna ring. Water boluses are placed against the skin to cool the surface and ensure uniform energy coupling. Comfort positioning is important โ sessions last over an hour.
- 3
Heat Delivery to 40โ43ยฐC
Radiofrequency power is gradually increased over 10โ15 minutes until tumour temperature reaches the therapeutic range. Power is then maintained for 60 minutes of plateau time โ the period during which the radiosensitisation or chemosensitisation effect is captured.
- 4
Radiation or Chemotherapy Coordination
Hyperthermia is timed to coincide with either a radiation fraction (delivered within 30โ60 minutes of the heat session) or chemotherapy infusion. Same-day, same-window scheduling is essential to capture the synergistic effect.
- 5
Cool-Down and Discharge
After the plateau, power is reduced and the patient is gradually cooled. Skin condition and vital signs are checked. Most patients go home the same day; an inpatient stay is rarely required for routine sessions.
Clinical Outcomes by Cancer Type
Phase III randomised trial data demonstrating the impact of deep regional hyperthermia when added to standard radiation or chemotherapy.
Cervical Cancer โ Dutch Deep Hyperthermia Group
Radiation alone vs radiation + deep regional hyperthermia in 358 patients with locally advanced cervical cancer.
- Complete Response โ RT Alone57%
- Complete Response โ RT + Deep HT83%
- 3-Year Overall Survival โ RT Alone27%
- 3-Year Overall Survival โ RT + Deep HT51%
Soft Tissue Sarcoma โ EORTC/ESHO 62961
Neoadjuvant ifosfamide-based chemo alone vs same chemo + deep regional hyperthermia in 341 patients.
- Response Rate โ Chemo Alone29%
- Response Rate โ Chemo + Deep HT44%
- 10-Year OS โ Chemo Alone37%
- 10-Year OS โ Chemo + Deep HT53%
Recurrent Rectal Cancer โ German Multicentre Trial
Re-irradiation with capecitabine vs re-irradiation with capecitabine + deep regional hyperthermia.
- Pain Response โ Chemoradiation Alone50%
- Pain Response โ Chemoradiation + Deep HT77%
Benefits and Limitations of Deep Regional Hyperthermia
Deep regional hyperthermia offers powerful clinical benefits โ but practical access, technical complexity, and patient-specific factors shape who can actually receive it.
Benefits
- Reaches Tumours Other Modalities CannotEffective for deep pelvic and abdominal tumours that surface hyperthermia cannot reach.
- Non-Invasive DeliveryNo incisions, no anaesthesia required for routine sessions; outpatient procedure.
- Synergises with Radiation and ChemotherapyBoosts radiation efficacy by up to 50% and amplifies platinum-based chemotherapy without raising drug dose.
- Enables Re-Irradiation in Recurrent DiseaseAllows lower-dose retreatment in previously irradiated fields with meaningful tumour response.
- No Significant Systemic ToxicityHeat is confined to the target region; the rest of the body remains at normal temperature.
Limitations
- Limited Centre AvailabilityPhased-array systems are expensive and operationally demanding; available at only a few centres globally.
- Patient Discomfort During Long SessionsLocal pressure or warmth, immobility for 90โ120 minutes, and the closed applicator can be uncomfortable.
- Body Habitus ConstraintsVery obese patients or those with metal implants in the treatment field may not be suitable due to power deposition issues.
- Requires Specialist Physics TeamOperating phased-array systems safely requires trained medical physicists, limiting which institutions can offer it.
- Inconsistent Insurance CoverageReimbursement varies; self-pay arrangements are common for international patients seeking treatment abroad.
Related Treatments & Resources
Explore the full hyperthermia knowledge base and related cancer treatment pages.
- Hyperthermia Therapy โ Full Treatment Page
- What Is Hyperthermia Therapy and How Does It Help Cancer Treatment?
- How Heat Makes Radiation Work Better: Radiosensitisation Explained
- How Heat Makes Chemotherapy Work Better: Drug-Heat Interactions
- Hyperthermia for Cervical Cancer
- Hyperthermia Therapy in China
Frequently Asked Questions
Common questions from patients and caregivers about deep regional hyperthermia for pelvic and abdominal tumours.
The Procedure
How does it feel to lie inside the hyperthermia applicator?
Most patients describe a sensation of warmth and mild pressure across the treatment region. The applicator itself does not touch the body โ only the cooling water bolus rests against the skin. Some patients feel localised warmth or tingling at specific spots, which the physicist can adjust by changing phase settings. Severe pain is uncommon and is a sign to pause and reposition.
How long does each session last and how many do I need?
Each session typically takes 90โ120 minutes from arrival to discharge, including setup, heating, and recovery. The actual heat plateau is 60 minutes. Most protocols pair hyperthermia with 4โ10 radiation fractions or chemotherapy cycles, delivered once or twice per week.
Is anaesthesia needed?
No. Deep regional hyperthermia is non-invasive and routine sessions do not require anaesthesia. If a tumour-temperature probe needs to be placed via catheter, that brief procedure may use local anaesthesia. Sedation is sometimes offered to patients who find the long immobility difficult.
What are the side effects?
Common side effects are mild and local โ skin warmth or redness at the bolus contact area, transient discomfort during heating, and occasional positional pain from lying still. Rare side effects include subcutaneous fat necrosis or blistering at hotspots; these are minimised by experienced operators and proper power adjustment. Serious complications are uncommon when standard temperature monitoring is followed.
Eligibility & Access
Am I a candidate for deep regional hyperthermia?
The best candidates have locally advanced or recurrent solid tumours in the pelvis or abdomen, are receiving radiation or chemotherapy, and have no metal implants in the treatment field. Body habitus, prior treatment history, and anatomy all factor into the decision. CancerFax can review your records and identify whether you are a suitable candidate.
Where can I access deep regional hyperthermia internationally?
Germany, the Netherlands, and Italy host the most established academic programmes โ including the centres that conducted the landmark phase III trials. China has rapidly expanded its capacity, with deep hyperthermia systems available at major cancer hospitals in Beijing, Shanghai, Guangzhou, and Chengdu, often at a fraction of European costs. Select centres in India also offer the treatment.
Will having a metal implant prevent me from getting deep hyperthermia?
Possibly, depending on the implant and its location. Metal in the direct treatment field can cause localised heating around the implant. Hip replacements, surgical clips, or spinal hardware in the pelvis often require either a different patient position, reduced power, or โ in some cases โ choosing an alternative therapy. The treating physics team makes this determination case by case.
How does CancerFax help patients access deep regional hyperthermia?
CancerFax reviews your medical records and identifies whether deep regional hyperthermia is technically and clinically appropriate. We shortlist centres based on tumour type, system availability (BSD-2000, Celsius TCS, EHY-2000), and cost. Our team coordinates appointment scheduling, interpreter services, visa support, and end-to-end logistics so the patient can focus on the treatment.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Could Deep Regional Hyperthermia Improve Your Treatment Outcome?
Upload your medical reports and our oncology team will review your case to determine whether deep regional hyperthermia โ combined with radiation or chemotherapy โ is suitable for your tumour, and identify the right specialist centre.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.